CRT Plus Chemo Did Not Improve RFS in Resected Gallbladder Cancer
Results from the ACCELERATE trial did not improve relapse-free survival when chemoradiation was added to chemotherapy for patients with resected gallbladder cancer.
Related Articles
Welcome! You are invited to join a webinar: Post-ASH 2024 MDS highlights webinar. After registering, you will receive a confirmation email about joining the webinar.
Join us to watch leading MDS experts present summaries on the most significant abstracts from ASH 2024 followed by interactive panel discussions debating current clinical…
BBO-8520 Receives FDA Fast Track Designation in KRAS G12C–Mutated Metastatic NSCLC
BBO-8520 has received FDA fast track designation in previously treated KRAS G12C–mutated metastatic non–small cell lung cancer.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
Brain Tumour Magazine: World Edition 2024/2025
The fourteenth annual edition of the official magazine of the International Brain Tumour Alliance (IBTA).
Treosulfan-based conditioning regimens for alloSCT in patients with myeloid malignancies
Eleni Gavriilaki, MD, PhD, Aristotle University of Thessaloniki, Thessaloniki, Greece, comments on the long-term safety and efficacy of treosulfan-based conditioning regimens for allogeneic stem cell…
World Cancer Day 2025: International Journal of Cancer
The International Journal of Cancer is a cancer journal from the Union for International Cancer Control covering experimental and clinical cancer research.
Novel Agents May Enhance JAK Inhibitor Efficacy and Augment the Myelofibrosis Treatment Paradigm
Naseema Gangat, MBBS, discusses clinical factors that she uses to choose the optimal JAK inhibitors for individual patients with myelofibrosis.
GSK’227 Earns FDA Breakthrough Therapy Designation for Late-Line R/R Osteosarcoma
The FDA has granted breakthrough therapy designation to GSK5764227 for the treatment of relapsed/refractory osteosarcoma.
First-Line Belzutifan/Cabozantinib Delivers Responses and Manageable Toxicities in ccRCC
Frontline belzutifan plus cabozantinib elicited durable responses and was tolerable in patients with treatment-naive advanced ccRCC.